Etrasimod Shows Sustained Efficacy Across Moderate and Severe Endoscopic Ulcerative Colitis
Etrasimod demonstrated significant induction and maintenance efficacy in patients with moderately to severely active ulcerative colitis (UC), regardless of baseline endoscopic severity, according to a post hoc analysis of the phase 3 ELEVATE UC 12 and ELEVATE UC 52 trials.
The findings provide clinically relevant reassurance for gastroenterologists treating patients with more advanced mucosal disease.
Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator approved for moderately to severely active UC. In this analysis, investigators evaluated outcomes by baseline Mayo endoscopic subscore, defining moderate disease as a score of 2 and severe disease as a score of 3. Efficacy was assessed at Week 12 in the pooled induction population and at Week 52 in the maintenance trial.
Among patients with moderate endoscopic disease, etrasimod consistently outperformed placebo. Clinical remission was achieved in 38.3% of etrasimod-treated patients versus 17.9% with placebo at Week 12, and in 36.5% versus 14.3% at Week 52 (P < .001 for both). Benefits were also evident in patients with severe endoscopic disease, a group often more difficult to treat. At Week 12, remission rates were 18.2% with etrasimod compared with 6.1% with placebo, increasing to 29.4% versus 3.4% at Week 52 (P < .001 for both).
Notably, patients with severe endoscopic disease appeared to derive increasing benefit over time. The proportion achieving key efficacy endpoints was generally higher at Week 52 than at Week 12, suggesting continued improvement beyond the induction phase. Subgroup analyses stratified by baseline modified Mayo score and prior biologic or Janus kinase inhibitor exposure showed broadly consistent results.
The authors concluded that “etrasimod demonstrated significant induction and maintenance efficacy over placebo in both moderate and severe endoscopic disease.” They further noted that “response to etrasimod in patients with severe endoscopic disease may continue to improve beyond 12-week induction therapy.”
Reference
Yarur AJ, Reinisch W, Chang S, et al. Efficacy of etrasimod in ulcerative colitis: analysis of ELEVATE UC 52 and ELEVATE UC 12 by baseline endoscopic severity. Clin Gastroenterol Hepatol. 2026;24(1):210-220.e3. doi:10.1016/j.cgh.2025.06.020
